Dexcom, Inc.

Obalon Therapeutics, Inc.

Reshape Lifesciences Inc.

Nanostructures, Inc.

Dex Com, Inc.

Shults, Mark

Brauker, James H.

Dubravka Markovic

Mark C Brister

Neil R Drake

Antonio C Llevares

Andrew P Rasdal

Amy D L VandenBerg

Peter C Simpson

James H Brauker

Mark Allan Tapsak

Matthew S Lake

Josefina Nider

Apurv Ullas Kamath

Michael Robert Mensinger

Sean T Saint

Paul V Neale

Nelson Quintana

Paul D Faucher

Kaushik Aroonkumar Patel

Jack Pryor

Robert James Boock

Matthew D Wightlin

Kum Ming Woo

Melissa A Nicholas

Arthur Chee

Lisa Nguyen

Seth R Brunner

Monica A Rixman

Victoria E Carr-Brendel

James R Petisce

Mark C Shults

Rathbun K Rhodes

Stuart J Updike

Philip E Mauger

Amy Dl VandenBerg

Monica A Rixman Swinney

Amy D L Vandenberg

Antonio Llevares

Amy D I Vandenberg

Amy DL Vandenberg

Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted.

Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided.

Intragastric device

Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.

Integrated delivery device for continuous glucose sensor

Intragastric volume-occupying devices and methods for treating obesity are provided. The devices, which are inflated by carbon dioxide, include an aluminum or silicon oxide barrier layer providing carbon dioxide retention and an alkylene vinyl alcohol polymer layer providing structural integrity in vivo.

Intragastric volume-occupying device and method for fabricating same

An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents.

The present disclosure relates to an implantable device having a frame and a flow restrictor. The frame includes a central portion and an end portion on either end of the frame. The flow restrictor is disposed within a lumen of the frame. The flow restrictor is configured to transition between a collapsed configuration and a deployed configuration. The flow restrictor may include a porosity configured to reduce fluid flow through the flow restrictor without completely occluding fluid flow.

Catheter based methods and devices for obstructive blood flow restriction

Growing community of inventors

San Diego, CA, United States of America

Dubravka Markovic